Table 1 HCV disease burden model input parameters
Parameter | Input | Year of estimate | Source |
|---|---|---|---|
Anti-HCV prevalence | 1.51% | 2022–2023 | First-year screening data |
Anti-HCV prevalence low | 1.20% | 2022–2023 | First-year screening data |
Anti-HCV prevalence high | 1.90% | 2022–2023 | First-year screening data |
Newly viraemic diagnosed | 11,769 | 2022–2023 | Calculated from screening data |
Number treated | 5269 | 2022–2023 | National Health Insurance Fund [21] |
Viraemic rate | 58.2% | 2022–2023 | Calculated from the data of pilot study in Klaipeda [18] |
Liver transplants | 32 | 2022 | Lithuanian National Transplant Bureau [22] |